Berenberg analyst Gaurav Goparaju initiated coverage of Exscientia with a Buy rating and $13 price target. Exscientia uses its artificial intelligence-enabled precision medicine platform to help develop novel drugs, the analyst tells investors in a research note. The firm says the company’s end-to-end patient-centric platform enables the development of drugs more quickly, more cheaply and with greater probabilities of clinical success than traditional approaches.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXAI:
- Exscientia initiates prospective observational study in ovarian cancer
- Exscientia enrolls first patient in ELUCIDATE study
- GT Apeiron announces enrollment of first patient in Phase 1/2 ELUCIDATE study
- Exscientia expands tech leadership team, CTO Pairaudeau stepping down
- Is EXAI a Buy, Before Earnings?